Tag: ReCor Medical
CMS grants transitional pass-through payment for Medtronic’s Symplicity Spyral and Recor’s...
The Centers for Medicare and Medicaid Services (CMS) has granted transitional pass-through (TPT) payment for Medtronic's Symplicity Spyral renal denervation (RDN) catheter and Recor...
First patients treated in US GPS study of Paradise renal denervation...
The first patients in the USA have been treated in Recor Medical’s Global Paradise System US Post Approval Study (US GPS), a real-world study...
Results on ReCor Medical’s Paradise ultrasound renal denervation system published in...
ReCor Medical and its parent company, Otsuka Medical Devices, recently announced that primary endpoint results from the RADIANCE II pivotal trial were published in...
Interventional News’ top 10 most popular stories of November 2022
Interventional News’ most popular stories last month included news of a US Food and Drug Administration pre-market approval submission of an ultrasound renal denervation...
Otsuka Medical Devices and ReCor Medical submit pre-market approval of Paradise...
Otsuka Medical Devices and ReCor Medical, a subsidiary of Otsuka, announce the filing of the pre-market approval (PMA) application to the US Food and...
ReCor Medical announces consistent reduction of blood pressure in pooled analysis...
ReCor Medical and its parent company, Otsuka Medical Devices, announced consistent and significant blood pressure-lowering results across a range of patients with uncontrolled hypertension,...
UK consensus statement on renal denervation “strongly encourages” clinicians to tell...
In a new consensus statement, the Joint UK Societies (JUKS)—which includes the British Society of Interventional Radiology—say that the evidence for renal denervation is “insufficient”...
